Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00846612 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetic Study of Avastin and Doxil in Ovarian Cancer
A Phase 1 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT00846612 is a Phase 1 study that has completed, run by NYU Langone Health. The registered enrollment target is 15 participants.
The verdict
NCT00846612, a Phase 1 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
This study is to study pharmacokinetics of Doxil using Doxil and Avastin on ovarian cancer patients who are resistant to or have relapsed from platinum-based therapy.
Interventions
- DRUG Doxil
- DRUG Bevacizumab (Avastin)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2008-01 |
| Est. Completion | 2012-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00846612
The ClinicalTrials.gov registry entry for NCT00846612 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Doxil is the first listed.
NCT00846612 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00846612 about?
NCT00846612 is a clinical study titled "Pharmacokinetic Study of Avastin and Doxil in Ovarian Cancer". This study is to study pharmacokinetics of Doxil using Doxil and Avastin on ovarian cancer patients who are resistant to or have relapsed from platinum-based therapy.
What is the current status of trial NCT00846612?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2008-01. Estimated completion is 2012-06.
What interventions are being tested in trial NCT00846612?
The interventions under investigation include: Doxil (DRUG), Bevacizumab (Avastin) (DRUG).
Who is sponsoring clinical trial NCT00846612?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.